BRD2 and fatty liver disease: Thus, the target screening for dyslipidemia, glucose abnormalities, and metabolic-associated fatty liver disease might be beneficial not only for Turner syndrome patients, as per current guidelines [50], but also for patients with non-syndromic POI and even for women with increased FSH levels for their age.